Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.81 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.63 |
| ▸ | LTA4H | P09960 | 7/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11151279 | 1.00 | HRH3 (0.81) | HRH3DRD3BACE1SLC6A2SLC6A4 | |
| SCHEMBL14970452 | 0.92 | HRH3 (0.89) | HRH3DRD3SLC6A2SLC6A4 | |
| SCHEMBL12741179 | 0.89 | HRH3 (1.00) | HRH3DRD3 | |
| SCHEMBL491968 | 0.88 | HRH3 (0.97) | HRH3DRD3SLC6A2SLC6A4 | |
| SCHEMBL5857248 | 0.86 | HRH3 (0.94) | HRH3DRD3SLC6A2SLC6A4 | |
| SCHEMBL4420934 | 0.84 | NPC1 (0.65) | HRH3DRD3SLC6A2SLC6A4LTA4H | |
| SCHEMBL4085732 | 0.84 | LTA4H (0.66) | HRH3BACE1LTA4HMAOB | |
| SCHEMBL4084094 | 0.84 | LTA4H (0.66) | HRH3BACE1LTA4HMAOB | |
| SCHEMBL1374727 | 0.84 | LTA4H (0.63) | HRH3DRD3SLC6A2SLC6A4LTA4H | |
| SCHEMBL7137996 | 0.84 | KCNH2 (0.75) | HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | SHANGHAI EAST HOSPITAL (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | HRH3 3036/4885DRD3 2103/4885BACE1 551/4885 |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | CACNA1F, CACNA1S, CACNA1D | HRH3 3036/4885DRD3 2103/4885BACE1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.